摘要
目的分析比较匹伐他汀钙与阿托伐他汀钙治疗冠心病的价值。方法80例冠心病患者,随机分为对照组和观察组,每组40例。对照组患者给予阿托伐他汀钙治疗,观察组患者给予匹伐他汀钙治疗。比较两组患者治疗前后临床指标[超敏C反应蛋白、心功能等级、左室射血分数、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)]、治疗效果、不良反应发生情况。结果观察组治疗前心功能等级、左室射血分数、超敏C反应蛋白、TC、LDL-C、TG、HDL-C水平分别为(3.31±1.11)级、(37.53±0.40)%、(16.13±3.93)mg/L、(6.62±0.51)mmol/L、(4.73±1.21)mmol/L、(2.12±0.94)mmol/L、(1.12±0.39)mmol/L,治疗后分别为(1.34±0.34)级、(54.62±0.26)%、(6.52±1.21)mg/L、(4.35±0.34)mmol/L、(2.72±0.58)mmol/L、(1.52±0.51)mmol/L、(2.22±0.38)mmol/L;对照组治疗前心功能等级、左室射血分数、超敏C反应蛋白、TC、LDL-C、TG、HDL-C水平分别为(3.32±1.13)级、(37.55±0.36)%、(16.23±3.91)mg/L、(6.61±0.53)mmol/L、(4.75±1.09)mmol/L、(2.11±0.79)mmol/L、(1.14±0.39)mmol/L,治疗后分别为(1.43±0.56)级、(54.18±0.37)%、(8.61±1.72)mg/L、(4.35±0.32)mmol/L、(2.78±0.57)mmol/L、(1.51±0.51)mmol/L、(1.36±0.45)mmol/L;治疗后,两组患者的心功能等级、超敏C反应蛋白、TC、LDL-C、TG水平均低于本组治疗前,左室射血分数、HDL-C水平均高于本组治疗前,且观察组患者的超敏C反应蛋白显著低于对照组,HDL-C水平显著高于对照组,差异具有统计学意义(P<0.05)。观察组治疗总有效率95.00%与对照组的92.50%比较,差异无统计学意义(P>0.05)。两组均无严重不良反应,两组患者不良反应发生率比较差异无统计学意义(P>0.05)。结论匹伐他汀钙与阿托伐他汀钙治疗冠心病的价值高,均能改善心功能和调节血脂,但是匹伐他汀钙可更好升高HDL-C和降低超敏C反应蛋白水平。
Objective To analyze and compare the value of pitavastatin calcium and atorvastatin calcium in the treatment of coronary heart disease.Methods A total of 80 patients with coronary heart disease were randomly divided into the control group and the observation group,with 40 cases in each group.Patients in the control group were treated with atorvastatin calcium,and patients in the observation group were treated with pitavastatin calcium.Both groups were compared in terms of clinical indicators[high-sensitivity C-reactive protein,cardiac function grading,left ventricular ejection fraction,total cholesterol(TC),triglycerides(TG),low-density lipoprotein cholesterol(LDL-C),high-density lipoprotein cholesterol(HDL-C)]before and after treatment,therapeutic effect,and occurrence of adverse reactions.Results In the observation group,the cardiac function grading,left ventricular ejection fraction,high-sensitivity C-reactive protein,TC,LDL-C,TG,and HDL-C were(3.31±1.11)grades,(37.53±0.40)%,(16.13±3.93)mg/L,(6.62±0.51)mmol/L,(4.73±1.21)mmol/L,(2.12±0.94)mmol/L,(1.12±0.39)mmol/L before treatment,and(1.34±0.34)grades,(54.62±0.26)%,(6.52±1.21)mg/L,(4.35±0.34)mmol/L,(2.72±0.58)mmol/L,(1.52±0.51)mmol/L,(2.22±0.38)mmol/L after treatment.In the control group,the cardiac function grading,left ventricular ejection fraction,high-sensitivity C-reactive protein,TC,LDL-C,TG,and HDL-C were(3.32±1.13)grades,(37.55±0.36)%,(16.23±3.91)mg/L,(6.61±0.53)mmol/L,(4.75±1.09)mmol/L,(2.11±0.79)mmol/L,(1.14±0.39)mmol/L before treatment,and(1.43±0.56)grades,(54.18±0.37)%,(8.61±1.72)mg/L,(4.35±0.32)mmol/L,(2.78±0.57)mmol/L,(1.51±0.51)mmol/L,(1.36±0.45)mmol/L after treatment.After treatment,the cardiac function grading,high-sensitivity C-reactive protein,TC,LDL-C,and TG of the two groups were lower than those of this group before treatment,and the left ventricular ejection fraction and HDL-C were higher than those of this group before treatment;the high-sensitivity C-reactive protein of the observation group was significantly lower than that of the control group,and the HDL-C was significantly higher than that of the control group;all the differences were statistically significant(P<0.05).The total effective rate 95.00%of the observation group was not statistically significant compared with 92.50%of the control group(P>0.05).No serious adverse reactions occurred in the two groups,and there was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Pitavastatin calcium and atorvastatin calcium are of high value in the treatment of coronary heart disease,both of which can improve cardiac function and regulate blood lipids,but pitavastatin calcium can better increase HDL-C and reduce hypersensitivity C reaction protein.
作者
薛洁
时启发
XUE Jie;SHI Qi-fa(Lyushunkou District Hospital of Traditional Chinese Medicine,Dalian 116041,China)
出处
《中国实用医药》
2021年第35期4-7,共4页
China Practical Medicine
关键词
匹伐他汀钙
阿托伐他汀钙
冠心病
价值
Pitavastatin calcium
Atorvastatin calcium
Coronary heart disease
Value
